Letter to the editorAllergen immunotherapy: No evidence of infectious risk
References (9)
Allergic rhinitis
Prim Care
(2008)- et al.
Allergen immunotherapy: a practice parameter third update
J Allergy Clin Immunol
(2011) - et al.
The impact of asthma control and higher maintenance doses on immunotherapy safety: year 5 of the AAAAI/ACAAI surveillance study
J Allergy Clin Immunol
(2015) - et al.
Allergen vial mixing and immunotherapy: risks of infections and vial contamination
Otolaryngol Head Neck Surg
(2007)
Cited by (12)
The prediction models of anaphylactic disease
2021, Informatics in Medicine UnlockedCitation Excerpt :The saturated IgE may prevent further fluctuations of allergic positive rates and frequencies as well. This conclusion also corresponds to other literatures about allergen immunotherapy [72–74]. As for deep learning model, we can obtain another figure in the 3D coordinate system as shown in Fig. 9, where the exponential coefficients are related to the potential capacity of plasma cell division and specific IgE production.
The infection rate of intralesional triamcinolone and the safety of compounding in dermatology for intradermal and subcutaneous injection: A retrospective medical record review
2020, Journal of the American Academy of DermatologyCitation Excerpt :Researchers within allergy and otolaryngology have demonstrated the safety of in-office immunotherapy preparation under clean technique. In the allergy literature, 2 prospective (136 in-office vials and 320 in-office immunotherapy injections) and 2 retrospective (26,795 and >130,000 subcutaneous allergen in-office immunotherapy injections) studies revealed negative vial cultures and no infections.13-15 To our knowledge, infection rates of compounded medications for dermatologic use have not been assessed.
Do no harm: Natural language processing of social media supports safety of aseptic allergen immunotherapy procedures
2019, Journal of Allergy and Clinical ImmunologyMining social media data to assess the risk of skin and soft tissue infections from allergen immunotherapy
2019, Journal of Allergy and Clinical ImmunologyCitation Excerpt :We identified a small number of posts describing a possible AIT-related SSTI using informatics methods (0.02%; 95% CI, 0.005%-0.043%). This study confirms findings to date from traditional studies that have found a negligible risk of infection for patients receiving AIT.6,10-12,14 Specifically, 1 previous retrospective study of 272 patients on AIT did not identify a single patient with SSTI from AIT, nor any patient with a fever, discharge from the injection site, or cellulitis.14
USP's revisions to sterile compounding standards and FDA guidance; impacts on mixing of allergen extracts
2018, Annals of Allergy, Asthma and ImmunologyEvaluation of the risk of infection associated with subcutaneous allergen immunotherapy: American Academy of Allergy, Asthma, and Immunology and American College of Allergy, Asthma, and Immunology National Surveillance Study on Allergen Immunotherapy, 2014–2015
2017, Annals of Allergy, Asthma and Immunology
Supported by the National Institutes of Health (grant T32 HL116275 to D.S.B.).
Disclosure of potential conflict of interest: D. S. Balekian has received a grant from the National Institutes of Health (T32 HL116275). The rest of the authors declare that they have no relevant conflicts of interest.